{"transactions":[{"id":4622982,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T23:01:43.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":10531,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":10531,"derivative":{"exercise_price":39.57,"expiration_date":"2036-09-15","underlying":"Common Shares","underlying_shares":10531},"source":{"system":"sec-edgar","filing":"0001209181-26-000007","document":"wk-form4_1789772501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000120918126000007/wk-form4_1789772501.xml","form_type":"4"}},{"id":4622981,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-18T23:01:43.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":5054,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 16, 2027, subject generally to the reporting person's service as a director through such date."}],"balance_after":111959,"source":{"system":"sec-edgar","filing":"0001209181-26-000007","document":"wk-form4_1789772501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000120918126000007/wk-form4_1789772501.xml","form_type":"4"}},{"id":4617446,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-09-14T22:25:45.000Z","date":"2026-09-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":2905,"price":40.94,"value":118930.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":106905,"source":{"system":"sec-edgar","filing":"0001209181-26-000005","document":"wk-form4_1789424742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000120918126000005/wk-form4_1789424742.xml","form_type":"4"}},{"id":705181,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-07-22T01:00:18.000Z","date":"2026-07-17","kind":"grant","planned":false,"acquired":true,"shares":405,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":109810,"source":{"system":"sec-edgar","filing":"0001140361-26-029193","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126029193/form4.xml","form_type":"4"}},{"id":727719,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:05:36.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000628","document":"wk-form4_1782338732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000628/wk-form4_1782338732.xml","form_type":"4"}},{"id":727718,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:05:36.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The 80,000 shares reported herein as indirectly owned through the James C. Momtazee Revocable Trust (the \"Trust\") were previously reported as directly owned by the Reporting Person."}],"balance_after":19070,"source":{"system":"sec-edgar","filing":"0001470831-26-000628","document":"wk-form4_1782338732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000628/wk-form4_1782338732.xml","form_type":"4"}},{"id":803707,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-04-21T22:32:58.000Z","date":"2026-04-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":94,"price":29.83,"value":2804.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":109405,"source":{"system":"sec-edgar","filing":"0001209181-26-000003","document":"wk-form4_1776810776.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000120918126000003/wk-form4_1776810776.xml","form_type":"4"}},{"id":803706,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-04-21T22:32:58.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":469,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":109499,"source":{"system":"sec-edgar","filing":"0001209181-26-000003","document":"wk-form4_1776810776.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000120918126000003/wk-form4_1776810776.xml","form_type":"4"}},{"id":933381,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-01-23T02:00:32.000Z","date":"2026-01-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":122,"price":22.98,"value":2803.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":109030,"source":{"system":"sec-edgar","filing":"0001140361-26-002087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126002087/form4.xml","form_type":"4"}},{"id":933380,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2026-01-23T02:00:32.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":109152,"source":{"system":"sec-edgar","filing":"0001140361-26-002087","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126002087/form4.xml","form_type":"4"}},{"id":1014664,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-10-23T01:01:00.000Z","date":"2025-10-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":158,"price":17.74,"value":2802.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":108543,"source":{"system":"sec-edgar","filing":"0001140361-25-038996","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125038996/form4.xml","form_type":"4"}},{"id":1014663,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-10-23T01:01:00.000Z","date":"2025-10-20","kind":"grant","planned":false,"acquired":true,"shares":789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":108701,"source":{"system":"sec-edgar","filing":"0001140361-25-038996","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125038996/form4.xml","form_type":"4"}},{"id":1041527,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-13T01:00:21.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":33726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date."}],"balance_after":33726,"derivative":{"exercise_price":13.77,"expiration_date":"2035-09-09","underlying":"Common Shares","underlying_shares":33726},"source":{"system":"sec-edgar","filing":"0001140361-25-034930","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125034930/form4.xml","form_type":"4"}},{"id":1041526,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-09-13T01:00:21.000Z","date":"2025-09-10","kind":"other","planned":false,"acquired":false,"shares":3282,"price":13.77,"value":45193.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":107912,"source":{"system":"sec-edgar","filing":"0001140361-25-034930","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125034930/form4.xml","form_type":"4"}},{"id":1041525,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-09-13T01:00:21.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":14524,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 10, 2026, subject generally to the reporting person's continuous service through such date."}],"balance_after":111194,"source":{"system":"sec-edgar","filing":"0001140361-25-034930","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125034930/form4.xml","form_type":"4"}},{"id":1084006,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-07-22T01:00:21.000Z","date":"2025-07-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":241,"price":11.65,"value":2807.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":96670,"source":{"system":"sec-edgar","filing":"0001140361-25-026648","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125026648/form4.xml","form_type":"4"}},{"id":1084005,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-07-22T01:00:21.000Z","date":"2025-07-17","kind":"grant","planned":false,"acquired":true,"shares":1201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":96911,"source":{"system":"sec-edgar","filing":"0001140361-25-026648","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125026648/form4.xml","form_type":"4"}},{"id":1102688,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T22:57:40.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":8425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":8425,"derivative":{"exercise_price":41.73,"expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":8425},"source":{"system":"sec-edgar","filing":"0000950170-25-089652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025089652/ownership.xml","form_type":"4"}},{"id":1102687,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T22:57:40.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":6589,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.  One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":95080,"source":{"system":"sec-edgar","filing":"0000950170-25-089652","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025089652/ownership.xml","form_type":"4"}},{"id":1168341,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-04-22T01:00:22.000Z","date":"2025-04-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":276,"price":10.15,"value":2801.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":95710,"source":{"system":"sec-edgar","filing":"0001140361-25-014801","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125014801/form4.xml","form_type":"4"}},{"id":1168340,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-04-22T01:00:22.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":1379,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":95986,"source":{"system":"sec-edgar","filing":"0001140361-25-014801","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125014801/form4.xml","form_type":"4"}},{"id":1294425,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-01-28T02:00:28.000Z","date":"2025-01-23","kind":"tax_withholding","planned":false,"acquired":false,"shares":306,"price":11.21,"value":3430.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."}],"balance_after":94607,"source":{"system":"sec-edgar","filing":"0001140361-25-002101","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125002101/form4.xml","form_type":"4"}},{"id":1294424,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-01-28T02:00:28.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":1248,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":94913,"source":{"system":"sec-edgar","filing":"0001140361-25-002101","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125002101/form4.xml","form_type":"4"}},{"id":1382360,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-10-24T01:00:21.000Z","date":"2024-10-21","kind":"grant","planned":false,"acquired":true,"shares":1231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":93665,"source":{"system":"sec-edgar","filing":"0001140361-24-044061","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124044061/form4.xml","form_type":"4"}},{"id":1406620,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-09-17T01:00:50.000Z","date":"2024-09-12","kind":"other","planned":false,"acquired":false,"shares":3056,"price":12.12,"value":37038.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the \"net settlement\" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs."}],"balance_after":92434,"source":{"system":"sec-edgar","filing":"0001140361-24-041232","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124041232/form4.xml","form_type":"4"}},{"id":1408587,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-13T01:00:19.000Z","date":"2024-09-10","kind":"grant","planned":false,"acquired":true,"shares":27894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date."}],"balance_after":27894,"derivative":{"exercise_price":12.19,"expiration_date":"2034-09-09","underlying":"Common Shares","underlying_shares":27894},"source":{"system":"sec-edgar","filing":"0001140361-24-040984","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124040984/form4.xml","form_type":"4"}},{"id":1408586,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-09-13T01:00:19.000Z","date":"2024-09-10","kind":"grant","planned":false,"acquired":true,"shares":16406,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 10, 2025, subject generally to the reporting person's continuous service through such date."}],"balance_after":95490,"source":{"system":"sec-edgar","filing":"0001140361-24-040984","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124040984/form4.xml","form_type":"4"}},{"id":1448662,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-07-26T01:00:54.000Z","date":"2024-07-23","kind":"grant","planned":false,"acquired":true,"shares":1555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":79091,"source":{"system":"sec-edgar","filing":"0001140361-24-034280","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124034280/form4.xml","form_type":"4"}},{"id":1469559,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-25T21:39:51.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":26014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer."}],"balance_after":26014,"derivative":{"exercise_price":27.36,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":26014},"source":{"system":"sec-edgar","filing":"0000950170-24-077448","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024077448/ownership.xml","form_type":"4"}},{"id":1534757,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-04-27T01:01:09.000Z","date":"2024-04-24","kind":"tax_withholding","planned":true,"acquired":false,"shares":293,"price":10.9,"value":3193.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the \"net settlement\" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":77536,"source":{"system":"sec-edgar","filing":"0001140361-24-022619","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124022619/form4.xml","form_type":"4"}},{"id":1534756,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-04-27T01:01:09.000Z","date":"2024-04-24","kind":"grant","planned":true,"acquired":true,"shares":1490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock covering Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":77829,"source":{"system":"sec-edgar","filing":"0001140361-24-022619","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124022619/form4.xml","form_type":"4"}},{"id":1672999,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2024-01-24T02:00:35.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":1570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock covering Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":76339,"source":{"system":"sec-edgar","filing":"0001140361-24-003554","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124003554/form4.xml","form_type":"4"}},{"id":1758121,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-10-19T01:30:25.000Z","date":"2023-10-17","kind":"other","planned":true,"acquired":false,"shares":687,"price":10.3,"value":7076.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering Common Shares. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":74769,"source":{"system":"sec-edgar","filing":"0001140361-23-048777","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123048777/form4.xml","form_type":"4"}},{"id":1758120,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-10-19T01:30:25.000Z","date":"2022-10-16","kind":"grant","planned":true,"acquired":true,"shares":1594,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of restricted stock covering Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein and the filing of this statement shall not be deemed an admission that the reporting person is, for purposes of Section 16 or otherwise, the beneficial owner of any of the reported securities."}],"balance_after":75456,"source":{"system":"sec-edgar","filing":"0001140361-23-048777","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123048777/form4.xml","form_type":"4"}},{"id":1776200,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-09-21T01:33:42.000Z","date":"2023-09-18","kind":"other","planned":false,"acquired":false,"shares":6752,"price":11.17,"value":75419.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the sale of Common Shares pursuant to a \"sell-to-cover\" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units (\"RSUs\") previously granted to the reporting person. This sale was effected pursuant to a \"sell to cover\" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4"}],"balance_after":73862,"source":{"system":"sec-edgar","filing":"0001140361-23-044653","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123044653/form4.xml","form_type":"4"}},{"id":1781030,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-15T01:31:09.000Z","date":"2023-09-12","kind":"grant","planned":false,"acquired":true,"shares":26595,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date."}],"balance_after":26595,"derivative":{"exercise_price":11.22,"expiration_date":"2033-09-11","underlying":"Common Shares","underlying_shares":26595},"source":{"system":"sec-edgar","filing":"0001140361-23-044043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123044043/form4.xml","form_type":"4"}},{"id":1781029,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-09-15T01:31:09.000Z","date":"2023-09-12","kind":"grant","planned":false,"acquired":true,"shares":17825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date."}],"balance_after":80614,"source":{"system":"sec-edgar","filing":"0001140361-23-044043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123044043/form4.xml","form_type":"4"}},{"id":1833822,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-07-07T01:30:24.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":1664,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":62789,"source":{"system":"sec-edgar","filing":"0001140361-23-033548","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123033548/form4.xml","form_type":"4"}},{"id":1845285,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:22:18.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":51501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":51501,"derivative":{"exercise_price":16.75,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":51501},"source":{"system":"sec-edgar","filing":"0001209191-23-039387","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123039387/doc4.xml","form_type":"4"}},{"id":1925074,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-04-06T01:31:58.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":1351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":61125,"source":{"system":"sec-edgar","filing":"0001140361-23-016868","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123016868/form4.xml","form_type":"4"}},{"id":2062682,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-01-06T02:30:43.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":2447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":59774,"source":{"system":"sec-edgar","filing":"0001140361-23-000728","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123000728/form4.xml","form_type":"4"}},{"id":2127121,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2022-11-02T21:57:44.000Z","date":"2022-10-31","kind":"grant","acquired":true,"shares":3404,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":57327,"source":{"system":"sec-edgar","filing":"0001140361-22-039660","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122039660/form4.xml","form_type":"4"}},{"id":2155691,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-20T01:53:39.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":68897,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date."}],"balance_after":68897,"derivative":{"exercise_price":3.5,"expiration_date":"2032-09-14","underlying":"Common Shares","underlying_shares":68897},"source":{"system":"sec-edgar","filing":"0001140361-22-033878","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122033878/form4.xml","form_type":"4"}},{"id":2155690,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true}}],"security":"Common Shares","published_at":"2022-09-20T01:53:39.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100%  on September 15, 2023, subject generally to the reporting person's continuous service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100%  on September 15, 2023, subject generally to the reporting person's continuous service through such date."}],"balance_after":53923,"source":{"system":"sec-edgar","filing":"0001140361-22-033878","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122033878/form4.xml","form_type":"4"}},{"id":2202811,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-07-25T10:06:05.000Z","date":"2022-07-20","kind":"grant","acquired":true,"shares":3923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an award of Common Shares received pursuant to the Company's Non-Employee Director Compensation Plan that was fully vested as of the grant date."}],"balance_after":3923,"source":{"system":"sec-edgar","filing":"0000899243-22-026616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000089924322026616/doc4.xml","form_type":"4"}},{"id":2222113,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:32:58.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":104921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":104921,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":104921},"source":{"system":"sec-edgar","filing":"0001209191-22-039259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122039259/doc4.xml","form_type":"4"}},{"id":2454428,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T00:47:00.000Z","date":"2021-12-29","kind":"purchase","acquired":true,"shares":80000,"price":14.5,"value":1160000.0,"ownership":{"direct":true},"balance_after":88491,"source":{"system":"sec-edgar","filing":"0000899243-22-000174","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924322000174/doc4.xml","form_type":"4"}},{"id":2647359,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T21:36:03.000Z","date":"2021-07-01","kind":"disposition_to_issuer","acquired":false,"shares":3521,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the \"Merger Agreement\"), dated as of February 24, 2021, by and among the Issuer, ICON plc (\"ICON\"), ICON US Holdings Inc. (\"US HoldCo\") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-088352","document":"tm2121280-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1209181/000110465921088352/tm2121280-4_4seq1.xml","form_type":"4"}},{"id":2658957,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T23:21:18.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":38895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date."}],"balance_after":38895,"derivative":{"exercise_price":62.63,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":38895},"source":{"system":"sec-edgar","filing":"0000899243-21-025402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924321025402/doc4.xml","form_type":"4"}},{"id":2682799,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T20:04:03.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock granted under the PRA Health Sciences, Inc. 2020 Stock Incentive Plan that will vest on June 1, 2022, subject to continued service on such date. Further, the grant shall vest in full upon a change in control as defined under the applicable award agreement."}],"balance_after":3521,"source":{"system":"sec-edgar","filing":"0001104659-21-076355","document":"tm2118302-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1209181/000110465921076355/tm2118302-6_4seq1.xml","form_type":"4"}},{"id":2971046,"issuer":{"id":134996,"kind":"organization","name":"Montes Archimedes Acquisition Corp","symbol":"MAAC"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class B common stock","published_at":"2020-11-20T22:36:30.000Z","date":"2020-11-20","kind":"other","acquired":false,"shares":1232044,"ownership":{"direct":false,"nature":"By Patient Square Capital LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-248802) under the heading \"Description of Securities-Founder Shares\", the shares of Class B common stock, par value $0.0001, will automatically convert into shares of Class A common stock, par value $0.0001, of the issuer at the time of the issuer's initial partnering transaction on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reflects the automatic surrender to the issuer of 1,285,637 of the issuer's shares of Class B common stock, par value $0.0001 per share, for no consideration by the Patient Square Capital LLC (the \"Sponsor\") pursuant to contractual arrangements with the issuer, triggered by the expiration of the option of the underwriter of the issuer's initial public offering to purchase additional units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-248802) under the heading \"Description of Securities-Founder Shares\", the shares of Class B common stock, par value $0.0001, will automatically convert into shares of Class A common stock, par value $0.0001, of the issuer at the time of the issuer's initial partnering transaction on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-248802) under the heading \"Description of Securities-Founder Shares\", the shares of Class B common stock, par value $0.0001, will automatically convert into shares of Class A common stock, par value $0.0001, of the issuer at the time of the issuer's initial partnering transaction on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As described in the issuer's registration statement on Form S-1 (File No. 333-248802) under the heading \"Description of Securities-Founder Shares\", the shares of Class B common stock, par value $0.0001, will automatically convert into shares of Class A common stock, par value $0.0001, of the issuer at the time of the issuer's initial partnering transaction on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities reported herein are held by the Sponsor. The reporting person controls the Sponsor, and as such has voting and investment discretion with respect to the securities held by the the Sponsor and may be deemed to have beneficial ownership of the securities held directly by the Sponsor. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":10167956,"derivative":{"underlying":"Class A common stock","underlying_shares":1232044},"source":{"system":"sec-edgar","filing":"0001104659-20-128061","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1209181/000110465920128061/a4.xml","form_type":"4"}},{"id":3122272,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-04T23:19:10.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":112422,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date."}],"balance_after":112422,"derivative":{"exercise_price":29,"expiration_date":"2030-06-01","underlying":"Common Stock","underlying_shares":112422},"source":{"system":"sec-edgar","filing":"0000899243-20-015304","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320015304/doc4.xml","form_type":"4"}},{"id":3140584,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-20T20:58:28.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":1748,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock that will vest on the first anniversary of the grant date, subject to continued service on such date."}],"balance_after":3191,"source":{"system":"sec-edgar","filing":"0001104659-20-064311","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1209181/000110465920064311/a4.xml","form_type":"4"}},{"id":3270925,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-15T00:16:47.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":24927,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24927,"derivative":{"exercise_price":34.65,"exercise_date":"2020-02-12","expiration_date":"2030-02-11","underlying":"Common Stock","underlying_shares":24927},"source":{"system":"sec-edgar","filing":"0000899243-20-004747","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320004747/doc4.xml","form_type":"4"}},{"id":3270924,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-15T00:16:47.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":8491,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8491,"source":{"system":"sec-edgar","filing":"0000899243-20-004747","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320004747/doc4.xml","form_type":"4"}},{"id":3341084,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-17T02:03:52.000Z","date":"2019-12-12","kind":"grant","acquired":true,"shares":82878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three annual installments after December 12, 2019, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":82878,"derivative":{"exercise_price":37.45,"expiration_date":"2029-12-11","underlying":"Common Stock","underlying_shares":82878},"source":{"system":"sec-edgar","filing":"0000899243-19-029353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924319029353/doc4.xml","form_type":"4"}},{"id":3437344,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-15T13:24:42.000Z","date":"2019-08-13","kind":"grant","acquired":true,"shares":1443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock that will vest on June 3, 2020, subject to continued service on such date."}],"balance_after":1443,"source":{"system":"sec-edgar","filing":"0001104659-19-046055","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1209181/000110465919046055/a4.xml","form_type":"4"}},{"id":4023599,"issuer":{"id":16119,"kind":"organization","name":"ENTELLUS MEDICAL INC","symbol":"ENTL"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-01T15:54:45.000Z","date":"2018-02-28","kind":"disposition_to_issuer","acquired":false,"shares":7500,"price":6.33,"value":47475.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option, which provided for vesting in 12 equal quarterly installments commencing on July 14, 2017, was canceled in the merger in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $24.00 over the per share exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":17.67,"expiration_date":"2027-07-14","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001235802-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374128/000123580218000031/primary_doc.xml","form_type":"4"}},{"id":4023598,"issuer":{"id":16119,"kind":"organization","name":"ENTELLUS MEDICAL INC","symbol":"ENTL"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2018-03-01T15:54:45.000Z","date":"2018-02-28","kind":"disposition_to_issuer","acquired":false,"shares":3750,"price":24,"value":90000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger, dated December 7, 2017, between Entellus Medical, Inc., Stryker Corporation and Explorer Merger Sub Corp. in exchange for a cash payment of $24.00 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001235802-18-000031","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374128/000123580218000031/primary_doc.xml","form_type":"4"}},{"id":4255232,"issuer":{"id":16119,"kind":"organization","name":"ENTELLUS MEDICAL INC","symbol":"ENTL"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-18T16:46:55.000Z","date":"2017-07-14","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests with respect to 1/12th of the shares subject to the option on each quarterly anniversary of July 14, 2017 (the \"Grant Date\") occurring over the three-year period immediately following the Grant Date, subject to the Reporting Person's continued service with the Company through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Mr. Momtazee is an executive of Kohlberg Kravis Roberts & Co. L.P. (together, with its affiliates, \"KKR\").  Mr. Momtazee is required to transfer to KKR the economic benefits of his compensation received in connection with his service on the board of directors of the Issuer.  Mr. Momtazee disclaims beneficial ownership over these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 of the Securities Exchange Act of 1934 or any other purpose."}],"balance_after":7500,"derivative":{"exercise_price":17.67,"expiration_date":"2027-07-14","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001235802-17-000104","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1374128/000123580217000104/primary_doc.xml","form_type":"4"}},{"id":4255231,"issuer":{"id":16119,"kind":"organization","name":"ENTELLUS MEDICAL INC","symbol":"ENTL"},"owners":[{"id":29296,"kind":"person","name":"MOMTAZEE JAMES C","position":1,"cik":"0001209181","reported_name":"MOMTAZEE JAMES C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2017-07-18T16:46:55.000Z","date":"2017-07-14","kind":"grant","acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Entellus Medical, Inc. 2015 Incentive Award Plan."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Mr. Momtazee is an executive of Kohlberg Kravis Roberts & Co. L.P. (together, with its affiliates, \"KKR\").  Mr. Momtazee is required to transfer to KKR the economic benefits of his compensation received in connection with his service on the board of directors of the Issuer.  Mr. Momtazee disclaims beneficial ownership over these securities, except to the extent of his pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 of the Securities Exchange Act of 1934 or any other purpose."}],"balance_after":3750,"source":{"system":"sec-edgar","filing":"0001235802-17-000104","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1374128/000123580217000104/primary_doc.xml","form_type":"4"}}]}